Agenda

• President
• President Elect
• Past-President
• Secretary
• Treasurer
• Director of Education
• Communications Committee
• TDM Journal
Topics to be discussed:
- Michael Oellerich
- Affiliate membership
- Developing countries fund
- Final report Kyoto meeting
- Standard of Practice committee
Michael Oellerich
Thank you Michael
Affiliate membership

- German Society of Clinical Laboratory (DGKL)
- Japanese Society for TDM
- The International Transplantation Society
- American College of Clinical Pharmacology
Developing countries fund

- Iguazu: USD $16,917
Kyoto 2017

- Final report
- Scientific success
- Positive financial balance
Standard of Practice Committee

- Standards of laboratory practice committee (1997)
- Later Standards of Practice Committee (2012)
- Phillip E. Morgan
- Simon Handley
## Membership Overview

<table>
<thead>
<tr>
<th>Type</th>
<th>Current</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Member</td>
<td>292</td>
</tr>
<tr>
<td>Young Scientist</td>
<td>225</td>
</tr>
<tr>
<td>Junior Member</td>
<td>77</td>
</tr>
<tr>
<td>Resigned</td>
<td>0</td>
</tr>
<tr>
<td>Retired</td>
<td>12</td>
</tr>
<tr>
<td>Honorary</td>
<td>6</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>612</strong></td>
</tr>
</tbody>
</table>
## Membership Overview

<table>
<thead>
<tr>
<th>Country</th>
<th>Amount</th>
<th>Country</th>
<th>Amount</th>
<th>Country</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>74</td>
<td>South Korea</td>
<td>7</td>
<td>Bulgaria</td>
<td>1</td>
</tr>
<tr>
<td>India</td>
<td>68</td>
<td>Taiwan</td>
<td>6</td>
<td>Cameroon</td>
<td>1</td>
</tr>
<tr>
<td>USA</td>
<td>68</td>
<td>Thailand</td>
<td>6</td>
<td>Estonia</td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td>42</td>
<td>Mexico</td>
<td>5</td>
<td>Ethiopia</td>
<td>1</td>
</tr>
<tr>
<td>China</td>
<td>33</td>
<td>South Africa</td>
<td>5</td>
<td>Former Yugoslav Republic of Slovenia</td>
<td>1</td>
</tr>
<tr>
<td>Australia</td>
<td>31</td>
<td>Spain</td>
<td>5</td>
<td>Ghana</td>
<td>1</td>
</tr>
<tr>
<td>Germany</td>
<td>27</td>
<td>New Zealand</td>
<td>4</td>
<td>Iran</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>22</td>
<td>Poland</td>
<td>4</td>
<td>Israel</td>
<td>1</td>
</tr>
<tr>
<td>Canada</td>
<td>20</td>
<td>Uzbekistan</td>
<td>4</td>
<td>Jamaica</td>
<td>1</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>19</td>
<td>Algeria</td>
<td>3</td>
<td>Kuwait</td>
<td>1</td>
</tr>
<tr>
<td>Belgium</td>
<td>18</td>
<td>Nepal</td>
<td>3</td>
<td>Liechtenstein</td>
<td>1</td>
</tr>
<tr>
<td>France</td>
<td>17</td>
<td>Tunisia</td>
<td>3</td>
<td>Mali</td>
<td>1</td>
</tr>
<tr>
<td>Sweden</td>
<td>12</td>
<td>Turkey</td>
<td>3</td>
<td>Mongolia</td>
<td>1</td>
</tr>
<tr>
<td>Norway</td>
<td>11</td>
<td>Czech Republic</td>
<td>2</td>
<td>Nambia</td>
<td>1</td>
</tr>
<tr>
<td>Switzerland</td>
<td>10</td>
<td>Denmark</td>
<td>2</td>
<td>Nigeria</td>
<td>1</td>
</tr>
<tr>
<td>Argentina</td>
<td>8</td>
<td>Hong Kong</td>
<td>2</td>
<td>Romania</td>
<td>1</td>
</tr>
<tr>
<td>Chile</td>
<td>8</td>
<td>Jordan</td>
<td>2</td>
<td>Sri Lanka</td>
<td>1</td>
</tr>
<tr>
<td>Colombia</td>
<td>8</td>
<td>Rwanda</td>
<td>2</td>
<td>Uruguay</td>
<td>1</td>
</tr>
<tr>
<td>Italy</td>
<td>8</td>
<td>Singapore</td>
<td>2</td>
<td>Vietnam</td>
<td>1</td>
</tr>
<tr>
<td>Egypt</td>
<td>7</td>
<td>Sudan</td>
<td>2</td>
<td>West Bank and Gaza Strip</td>
<td>1</td>
</tr>
<tr>
<td>Malaysia</td>
<td>7</td>
<td>Austria</td>
<td>1</td>
<td>Zimbabwe</td>
<td>1</td>
</tr>
</tbody>
</table>
President-Elect Report

Yusuke Tanigawara
15th IATDMCT Congress (2017, Kyoto)

- Congress archives on the web
- All programs and speakers
- All abstracts
- Pictures
- Final report
- All related information

The Congress surplus USD 70,000 is transferred and saved on ‘Developing country fund’ for use to support developing countries in future Congresses.
Upcoming IATDMCT Congresses

- 2019  Iguazu, Brazil
- 2020  Banff, Canada
- 2021  Rome, Italy
- 2022  ? / 3 bids
17th IATDMCT Congress (2019, Iguassu)

- Main Theme "Therapeutic Monitoring of Drugs and Clinical Toxicology for a Globalized World"
- Chair, Dr. Rafael Linden, Universidade Feevale
- Website: www.iatdmct2019.org
17th IATDMCT Congress (2019, Iguassu)

- Important dates
  - 1 October 2018: Registration and abstract submission open
  - 29 March 2019: Abstract submission deadline
  - 31 May 2019: Abstract notification to authors
  - 30 June 2019: Early registration deadline
  - 15 September 2019: Website registration closes
  - 22-26 September 2019: Congress
20th Congress in 2022

- 3 bids
- Guadalajara, Mexico
- Oslo, Norway
- Prague, Czech Republic

The decided venue will be disclosed at the closing ceremony on Wednesday.
Past-President

Lorale Langman
Because we are moving to annual meetings we are “splitting” the awards we offer each year.

<table>
<thead>
<tr>
<th>Even years - 2018</th>
<th>Odd years - 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>C.E. Pippenger Award</td>
<td>Irving Sunshine Award</td>
</tr>
<tr>
<td>Victor Armstrong Young Investigator Award</td>
<td>Patsalos Prize</td>
</tr>
</tbody>
</table>
Awards for 2018

C.E. Pippenger Award
- Presented for Outstanding Contributions to Therapeutic Drug Monitoring
- Roger W Jelliffe
Awards for 2018

Victor Armstrong Young Investigator Award
- Presented to a Young Investigator for Exceptional Scientific Achievements
  - Laure Elens
Thank you
Merci
Secretary Report

Maria Shipkova
Stuttgart, Germany
Secretary Report

- Membership Report
  - Updated IATDMCT Membership Summary (as of August 31, 2018)

<table>
<thead>
<tr>
<th>Type</th>
<th>Total 2017</th>
<th>Total 2018</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Member</td>
<td>296 (45%)</td>
<td>292 (48%)</td>
<td>-1.35</td>
</tr>
<tr>
<td>Young Scientist</td>
<td>229 (34%)</td>
<td>225 (37%)</td>
<td>-1.75</td>
</tr>
<tr>
<td>Junior Member</td>
<td>113 (17%)</td>
<td>77 (13%)</td>
<td>-31.6</td>
</tr>
<tr>
<td>Member Award</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Resigned</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Retired</td>
<td>19</td>
<td>12</td>
<td>-36.8</td>
</tr>
<tr>
<td>Honorary</td>
<td>6</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL</td>
<td>664</td>
<td>612</td>
<td>-7.8</td>
</tr>
</tbody>
</table>
Secretary Report

- **Loss Members/Country**
  - China 28
  - Japan 21
  - Netherlands 13
  - USA 7
  - Canada 7

- **Gain Members/Country**
  - India 17
  - Australia 10
  - Brazil 7
  - Columbia 4
Member-Get-A-Member Campaign 2018
The Campaign started on January 1st and ended on August 31st, 2018. The winners get free registration for the Brisbane Congress.

29 new members in total

Congratulations to:

Dr. Nicolas Venisse
(France)

Dr. Cindy Lau
(Australia)
Terms of reference: Affiliate Membership

- The IATDMCT is unique in its goal to promote the interest of Therapeutic Drug Monitoring and Clinical Toxicology internationally. **It collaborates with a selected group of affiliated scientific societies that share its aims particularly on a national level.** This synergistic relationship provides a platform for open collaboration and exchange of knowledge and experiences.

- Members of affiliated societies may join IATDMCT and enjoy the **full function of IATDMCT membership benefits.** Their IATDMCT dues will be reduced by $ 20 (US) based on the FULL membership or YOUNG SCIENTIST membership fees of IATDMCT. The IATDMCT benefit of a 10% saving on the fee for a two-year membership remains unaffected. The $ 20 (US)/year discount will apply on top of it.

- Eligible for this membership category are members of scientific societies with which a **respective agreement is in place.** Depending on this agreement additional benefits (e.g. reduction of the dues for the affiliated scientific society) may be available. For further information check with your society.

- The IATDMCT looks forward to expanding the network with other societies with similar visions and interests in Therapeutic Drug Monitoring and Clinical Toxicology to foster personalized medicine worldwide. **Scientific societies interested in this form of collaboration can contact info@iatdmct.org** for more details.
How to apply for “Affiliate membership” at IATDMCT:

- Login to our website at [www.iatdmct.org](http://www.iatdmct.org)
- Complete the IATDMCT Membership Application Form by selecting “Affiliate membership” as the membership category. To do this you can use either the online- or the PDF application form.
- **Send the form together with a proof of the payment of the membership fee at the partner society to either:**
  - Email: info@iatdmct.org
  - Fax: 1-613-531-0626
  - Mail to: IATDMCT
    4 Cataraqui Street, Suite 310
    Kingston ON, K7K 1Z7 Canada
- Pay by Credit Card (we accept Visa and MasterCard) or by Check
Secretary Report

Affiliate Membership: Potential Partners

- JATDM
- AACP
- TTS
- .......
Secretary report

Other:

Travel grants IATDMCT Congresses:
- previous rules (5 grants a 2000 $ US)
- the competition in the past was very strong, numerous applicants with equal quality
- usual practice: only once and preferably citizens of developing countries
- applications from IATDMCT members who are very active for IATDMCT (CC members)

for 2018: 15 grants a 1000 $ US
Treasurer Report

Denise A McKeown
Forensic Medicine and Science, University of Glasgow
Glasgow, UK
2017 Financials: Overview

• 2017 Revenue: $304,860 ($XXX,XXX)
  – TDM Journal Royalties: $260,224
  – Membership Fees: $41,302
  – Awards Revenue: $3,334
  – 2017 Congress Surplus: $XX,XXX

• Expenses: $182,889
  – TDM Journal Related: $113,141
  – Administrative Fees: $28,291
  – Membership Services: $41,458

• Surplus: $121,971 ($XXX,XXX)
2017 Financials: Administration Expenses

• Administration Expenses: $28,291
  – Management Fee: $15,000.00
  – Telecommunications: $669.69
  – Administration Expenses: $9,326.71
  – Professional Fees: $3,294.50
2017 Financials: Membership Services Expenses

- Membership Services Expenses: $41,458
  - Website: $4,975.71
  - IATDMCT Compass: $9037.03
  - Award Winners: $6,217.71
  - International Travel Grants: $10,037.00
  - Meetings: $11,040.07
  - Sundry Expenses: $150
2017 Financials: Summary

• IATDMCT Assets
  – Remain strong

• Annual Treasurer Report
  – As a result of 2017 AGM member feedback a detailed Annual Treasurer Report will be produced
  – To be circulated via email to members and posted on the Members Only Area of the IATDMCT website
  – 2017 Report - to be circulated following the finalisation of the 2017 financials
  – 2018 Report - will be circulated once 2018 financials finalised
Queries or Questions?

• Contact
  – denise.mckeown@glasgow.ac.uk
Communications Committee

Kamisha Johnson-Davis (Chair)
Salt Lake City, UT, USA

Ofelia Noceti (Vice-Chair)
Montevideo, Uruguay

Denise McKeown
Glasgow, UK

Edgar Spencer
England, UK

Maria Shipkova
Stuttgart, Germany

Franck Saint-Marcoux
Limoges, France

Nicolas Picard
Limoges, France

Paula Schaiquevich
Buenos Aires, Argentina

Eberhard Weiland
Stuttgart, Germany

Violette Gijsen
Rotterdam, The Netherlands

Manuela Neuman
Toronto, Canada

Olga Millan Lopez
Barcelona, Spain

Alain Verstraete
Gent, Belgium

Jana Stojanova
Chile, South America

Ryuji Kato
Osaka, Japan

Sarah Wille
Brussels, Belgium

Markus Meyer
Heidelberg, Germany

Lewis Couchman
London, UK
Thank you

- Local Organizing Committee (Andrew McLachlan, Ross Norris, Lidia Dalton, Stephanie McMahon)
- IATDMCT Office (Amy Jiang, Pamela Lyons)
- Communication Committee members
- IATDMCT Council
Compass Quarterly Newsletter

Compass team have done an outstanding job during 2018!

Associate Editor: Edgar Spencer  England, UK
Editor-in-Chief: Paula Schaiquevich  Buenos Aires, Argentina
Associate Editor: Franck Saint-Marcoux  Limoges, France
IATDMCT Social Media Team

- @IATDMCT on Twitter (>3000 tweets, 986 followers)
  Purpose: real time information on the latest topics
  Managers: Olga Millan, Jana Stojanova, Ryuji Kato, Nicolas Picard, Lewis Couchman

- IATDMCT Group on LinkedIn (780 members)
  Purpose: interactive scientific discussion
  Managers: Ofelia Noceti, Maria Shipkova, Ryuji Kato

- IATDMCT Blog (monthly posts)
  Purpose: on-line space to communicate to members and non-members
  Posts: interviews with IATDMCT members, news highlights
  Author: Jana Stojanova, Editors: Denise McKeown & Maria Shipkova

- IATDMCT Facebook (145 likes, 154 friends)
  Purpose: informal platform to communicate scientific news
  Manager: Violette Gijsen, Kamisha Johnson-Davis

Thank you team!
## Blog 2018

<table>
<thead>
<tr>
<th>MONTH</th>
<th>BLOG TOPIC</th>
<th>NUMBER OF HITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>JANUARY</td>
<td>TEUN VAN GELDER</td>
<td>746</td>
</tr>
<tr>
<td>FEBRUARY</td>
<td>JIANGTAO TANG</td>
<td>392</td>
</tr>
<tr>
<td>MARCH</td>
<td>KAMISHA JOHNSON-DAVIS</td>
<td>374</td>
</tr>
<tr>
<td>APRIL</td>
<td>MANUELA NEUMAN</td>
<td>330</td>
</tr>
<tr>
<td>MAY</td>
<td>Influence of Inflammation on Voriconazole metabolism</td>
<td>274</td>
</tr>
<tr>
<td>JUNE</td>
<td>2017 Charles Pippenger and Irvine Sunshine Award Winners</td>
<td>155</td>
</tr>
<tr>
<td>JULY</td>
<td>NICOLAS PICARD</td>
<td>110</td>
</tr>
<tr>
<td>AUGUST</td>
<td>JENNIFER MARTIN</td>
<td>92</td>
</tr>
<tr>
<td>SEPTEMBER</td>
<td>INDY SANDARADURA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ANDREW MCLACHLAN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOPHIE STOCKER</td>
<td></td>
</tr>
</tbody>
</table>
IATDMCT Communication Activities

- IATDMCT E-News (monthly)
  - Purpose: Latest topics & news communicated via email to members
  - Topics: Office news, Congress updates, advertisements etc
  - New report of academic activities of members from the Scientific Committees
  - Co-Editors: Maria Shipkova and Manuela Neuman

- LWW TDM Journal Adverts (every issue)
  - Purpose: free advertising space to promote IATDMCT
  - Adverts: Congress 2018, social media, website resources, scientific committees
  - Managers: Denise A McKeown
IATDMCT Website – Resources Area

Thank you

- Members/Speakers for providing material (webinars, presentations, articles, etc.)
- IATDMCT Office for populating the material on the website & for their guidance
- Education Committee – select content material for website
  Katharina Rentsch
  Eric van Maarseveen
  Staffan Rosenborg
IATDMCT Congress 2018

- Remember to download the Congress App for up to date information for the Congress

- 2nd Congress to provide Local Poster Printing Service
Education Director Report

Erik van Maarseveen
UMC Utrecht

Katharina Rentsch
University Hospital Basel

Staffan Rosenborg
Karolinska University Hospital
Activities of Directors of Education

- Posting of webcast presentation of previous meetings on Resources area
  - Including promotions in IATDMCT e-news updates

- Selection of talk taping for Brisbane congress

- First educational symposium at 2018 congress
  - Highlight!
Future plans of Directors of Education

– Online posting congress materials *asap* after congress
  • For early access to IATDMCT members

– Discuss online Drug monographs in resources area
  • In close collaboration with IATDMCT SCs
2017
European Office Editorial Report

Prof. Dr. med Dr. h.c. Michael Oellerich
FAACC, FAMM, FFPath (RCPI), FRCPath
Editor-in-Chief

Prof. Philip N. Patsalos
PhD, FRCPath
Associate Editor

Hannah Hempstead
Managing Editor Europe
**Impact Factor 1996 – 2017**

- 1996 – 1.829
- 1997 – 1.836
- 1998 – 1.543
- 1999 – 1.383
- 2000 – 1.732
- 2001 – 2.049
- 2002 – 2.140
- 2003 – 2.372
  - 2004 – 2.798
  - 2005 – 2.718
  - 2006 – 3.032
- 2007 – 2.392
- 2008 – 2.410
- 2009 – 2.429
- 2010 – 3.127
- 2011 – 2.491
- 2012 – 2.234
- 2013 – 1.926
- 2014 – 2.376
- 2015 – 2.094
- 2016 – 2.178
- 2017 – 2.092

*5 Year Impact Factor: 2.1332*
Impact Factor 1995 - 2017

Professor Michael Oellerich begins his tenure as Editor-in-Chief of Therapeutic Drug Monitoring.
## Manuscript Influx

Manuscripts received by the European Office:

<table>
<thead>
<tr>
<th>Year</th>
<th>Manuscripts Received</th>
</tr>
</thead>
<tbody>
<tr>
<td>2009</td>
<td>132</td>
</tr>
<tr>
<td>2010</td>
<td>125</td>
</tr>
<tr>
<td>2011</td>
<td>123</td>
</tr>
<tr>
<td>2012</td>
<td>170</td>
</tr>
<tr>
<td>2013</td>
<td>140</td>
</tr>
<tr>
<td>2014</td>
<td>151</td>
</tr>
<tr>
<td>2015</td>
<td>126</td>
</tr>
<tr>
<td>2016</td>
<td>142</td>
</tr>
<tr>
<td>2017</td>
<td>171</td>
</tr>
</tbody>
</table>
The number of submissions received in 2017 were:

- Original Articles: 134
- Short Communications: 26
- Letters to the Editor: 8
- Review Articles: 3
# Acceptance Rates

For manuscripts *received* in 2017:

- 44% accepted
- 45% rejected after peer review
- 10% rapidly rejected
- 1% pending

Submitted manuscripts to the European Office by *Country of Origin* in 2017

**Top 10**

<table>
<thead>
<tr>
<th>Country</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td>32</td>
</tr>
<tr>
<td>Japan</td>
<td>20</td>
</tr>
<tr>
<td>The Netherlands</td>
<td>18</td>
</tr>
<tr>
<td>France</td>
<td>10</td>
</tr>
<tr>
<td>Italy</td>
<td>10</td>
</tr>
<tr>
<td>Spain</td>
<td>10</td>
</tr>
<tr>
<td>Norway</td>
<td>8</td>
</tr>
<tr>
<td>Germany</td>
<td>7</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>6</td>
</tr>
<tr>
<td>Australia</td>
<td>5</td>
</tr>
</tbody>
</table>
### Status of submitted manuscripts to the European Office in 2017

<table>
<thead>
<tr>
<th>Country</th>
<th>Accept</th>
<th>Reject</th>
<th>Pending</th>
<th>Rapid Reject</th>
<th>Withdrawn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>6</td>
<td>26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Croatia</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Estonia</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>6</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iran</td>
<td>2</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>5</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td>11</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lebanon</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morocco</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netherlands</td>
<td>13</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Zealand</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nigeria</td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norway</td>
<td>6</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palestine</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Portugal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia &amp; Montenegro</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Singapore</td>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Korea</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Switzerland</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taiwan</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tunisia</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkey</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td>4</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USA</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
All submitted manuscripts in 2017 by Country of Origin
2017 Turnaround Times

- The time from submission to published ahead of print: 21 weeks
  - The time from acceptance to published ahead of print: 5 weeks
  - The time from submission to print: 29 weeks (2016: 25 weeks)
  - The time from acceptance to print: 13 weeks (2016: 12 weeks)

- The page usage quota was 800 pages for 2017 (2016: 840). 686 pages in total were used against the budget, meaning we were under the budget by 154 pages.

- The current European backlog (after the August 2018 issue) includes 5 manuscripts.
## Manuscript Rating

In % of total accepted and rejected manuscripts

<table>
<thead>
<tr>
<th></th>
<th>2017</th>
<th></th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority 1:</td>
<td>1%</td>
<td></td>
<td>3%</td>
</tr>
<tr>
<td>Priority 2:</td>
<td>17%</td>
<td></td>
<td>35%</td>
</tr>
<tr>
<td>Priority 3:</td>
<td>40%</td>
<td></td>
<td>57%</td>
</tr>
<tr>
<td>Priority 4:</td>
<td>42%</td>
<td></td>
<td>5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th></th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority 1:</td>
<td>1%</td>
<td></td>
<td>1%</td>
</tr>
<tr>
<td>Priority 2:</td>
<td>14%</td>
<td></td>
<td>32%</td>
</tr>
<tr>
<td>Priority 3:</td>
<td>28%</td>
<td></td>
<td>57%</td>
</tr>
<tr>
<td>Priority 4:</td>
<td>57%</td>
<td></td>
<td>10%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th></th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priority 1:</td>
<td>2%</td>
<td></td>
<td>5%</td>
</tr>
<tr>
<td>Priority 2:</td>
<td>18%</td>
<td></td>
<td>33%</td>
</tr>
<tr>
<td>Priority 3:</td>
<td>50%</td>
<td></td>
<td>49%</td>
</tr>
<tr>
<td>Priority 4:</td>
<td>30%</td>
<td></td>
<td>13%</td>
</tr>
</tbody>
</table>
2017 Manuscript Rating

Rating

- Priority 1: 1%
- Priority 2: 14%
- Priority 3: 28%
- Priority 4: 57%
2018 Interim European Office Editorial Report

Prof. Dr. med Dr. h.c. Michael Oellerich
FAACC, FAMM, FFPath (RCPI), FRCPath
Editor-in-Chief

Prof. Philip N. Patsalos
PhD, FRCPath
Associate Editor

Hannah Hempstead
Managing Editor Europe
Acceptance Rates 2018*

For manuscripts *received* in 2018:
26% accepted
26% rejected after peer review
9% rapidly rejected
39% pending

Submitted manuscripts to the European Office by *Country of Origin* in 2018

**Top 10**

1. China : 16**
2. Japan : 6
3. France: 4
4. Germany : 4
5. Italy : 3
6. Norway : 3
7. Australia: 2
8. Iran: 2
9. Croatia: 1
10. The Netherlands : 1

**13 of which were transferred to the US Office**
Manuscripts received by the European Office

The number of submissions received in 2018* are:

- Original Articles: 49
- Short Communications: 3
- Letter to the Editor: 1

*as of June 12, 2018.
Turnaround Times

- The time from submission to published ahead of print: 14 weeks
  - The time from acceptance to published ahead of print: 1 week
  - The time from submission to print: 26 weeks (2017: 29 weeks)
  - The time from acceptance to print: 14 weeks (2017: 13 weeks)

- The page usage quota is 800 pages for 2018 (2017: 800). 396 pages in total have been used against the budget, meaning 444 pages are left.

- The current European backlog (after the August 2018 issue) includes 5 manuscripts.

Manuscript Rating

Priority 1: 0%
Priority 2: 15%
Priority 3: 56%
Priority 4: 29%
2018 Interim Denver Office
Editorial Report*

Uwe Christians MD, PhD
Editor-in-Chief

Philip Patsalos, PhD
Associate Editor

Maria Shipkova, MD
Reviews Editor

Wanzhu Zhao, MA
Managing Editor

*01/01/2018-06/12/2018
Submission types processed at the Denver Office: North America and Chinese Original Articles, all Review Articles.
Acceptance Rate

From 01/01/2018 to 06/13/2018

- Total manuscripts received: 67
- Accept: 40%
- Reject: 46%
- Pending: 13%
# Manuscripts Ratings (1-5)

<table>
<thead>
<tr>
<th>Article Type</th>
<th>Clinical relevance</th>
<th>Scientific or clinical contribution</th>
<th>Presents new information</th>
<th>Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Manuscript</td>
<td>2.49</td>
<td>2.6</td>
<td>2.43</td>
<td>2.55</td>
</tr>
<tr>
<td>Review Article</td>
<td>2.46</td>
<td>2.75</td>
<td>2.92</td>
<td>2.58</td>
</tr>
<tr>
<td>Adjusted Averages</td>
<td>2.233</td>
<td>2.59</td>
<td>2.62</td>
<td>2.66</td>
</tr>
</tbody>
</table>
# Editorial Office Turnaround Time

<table>
<thead>
<tr>
<th>Step</th>
<th>Average Number of Days</th>
<th>2017 Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to Editor Assignment</td>
<td>0.7 (2017: 1.9)</td>
<td></td>
</tr>
<tr>
<td>Submission to Reviewer Invitation</td>
<td>1.2 (2017: 3.6)</td>
<td></td>
</tr>
<tr>
<td>Submission to First Decision</td>
<td>29.8 (2017: 38.4)</td>
<td></td>
</tr>
</tbody>
</table>

# Production Turnaround Time

<table>
<thead>
<tr>
<th>Step</th>
<th>Average Number of Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to In Production</td>
<td>11 weeks</td>
</tr>
<tr>
<td>Final Decision to In Production</td>
<td>3 weeks</td>
</tr>
<tr>
<td>Submission to Actual Print</td>
<td>26 weeks</td>
</tr>
</tbody>
</table>
2018 Editorial Report*

Uwe Christians MD, PhD
Editor-in-Chief

Philip Patsalos, PhD
Associate Editor

Maria Shipkova, MD
Reviews Editor

Wanzhu Zhao, MA
Managing Editor

*After 06/13/2018
Acceptance Rate

From 06/13/2018 - now
Total manuscripts received: 49
- Accept: 4%
- Reject: 20%
- Pending: 76%
Submission Types

- Original Manuscript: 65%
- Review Article: 21%
- Letter to the Editor: 6%
- Short Communication: 6%
- Grand Round: 2%

Counts:
- Original Manuscript: 32
- Review Article: 10
- Letter to the Editor: 3
- Short Communication: 3
- Grand Round: 1
Manuscripts Received by Country of Origin

Belgium 1
Brazil 4
China 11
France 3
Germany 5
India 1
Italy 1
Japan 3
Korea 1
Mexico 1
Netherlands 5
Norway 2
Spain 2
Sweden 1
Thailand 1
UK 3
United States 3
Malaysia 1
### Editorial Office Turnaround Time

<table>
<thead>
<tr>
<th>Step</th>
<th>Average Number of Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to Editor Assignment</td>
<td>1.3 (2017: 1.9)</td>
</tr>
<tr>
<td>Submission to Reviewer Invitation</td>
<td>3.6 (2017: 3.6)</td>
</tr>
<tr>
<td>Submission to First Decision</td>
<td>20.3 (2017: 38.4)</td>
</tr>
</tbody>
</table>

### Production Turnaround Time

<table>
<thead>
<tr>
<th>Step</th>
<th>Average Number of Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to In Production</td>
<td>4 Weeks</td>
</tr>
<tr>
<td>Submission to PAP</td>
<td>No sufficient Data</td>
</tr>
<tr>
<td>Submission to Print</td>
<td>No sufficient Data</td>
</tr>
</tbody>
</table>
The current European backlog (after the December 2018 issue) includes 6 manuscripts.

<table>
<thead>
<tr>
<th>Issue Month</th>
<th>Total Pages counted against budget</th>
<th># pages over (+)/under(-) allowance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb</td>
<td>163</td>
<td>22</td>
</tr>
<tr>
<td>Apr</td>
<td>131</td>
<td>-10</td>
</tr>
<tr>
<td>June</td>
<td>102</td>
<td>-38</td>
</tr>
<tr>
<td>Aug</td>
<td>137</td>
<td>-3</td>
</tr>
<tr>
<td>Oct</td>
<td>148</td>
<td>9</td>
</tr>
<tr>
<td>Dec</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Manuscripts Ratings (1-5)

<table>
<thead>
<tr>
<th>Article Type</th>
<th>Clinical relevance</th>
<th>Scientific or clinical contribution</th>
<th>Presents new information</th>
<th>Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter to the Editor</td>
<td>2.5</td>
<td>2.33</td>
<td>2.67</td>
<td>2.33</td>
</tr>
<tr>
<td>Original Manuscript</td>
<td>2.12</td>
<td>2.7</td>
<td>2.48</td>
<td>2.68</td>
</tr>
<tr>
<td>Review Article</td>
<td>2.5</td>
<td>2.75</td>
<td>2.75</td>
<td>2.75</td>
</tr>
<tr>
<td>Short Communication</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td><strong>Adjusted Averages</strong></td>
<td><strong>2.53</strong></td>
<td><strong>2.7</strong></td>
<td><strong>2.48</strong></td>
<td><strong>2.69</strong></td>
</tr>
</tbody>
</table>


Impact Factor 1996-2017

- 1996 – 1.829
- 1997 – 1.836
- 1998 – 1.543
- 1999 – 1.383
- 2000 – 1.732
- 2001 – 2.049
- 2002 – 2.140
- 2003 – 2.372
- 2004 – 2.798
- 2005 – 2.718
- 2006 – 3.032
- 2007 – 2.392
- 2008 – 2.410
- 2009 – 2.429
- 2010 – 3.127
- 2011 – 2.491
- 2012 – 2.234
- 2013 – 1.926
- 2014 – 2.376
- 2015 – 2.094
- 2016 – 2.178
- 2017 – 2.092
## Current Editorial Office Manuscript Status

<table>
<thead>
<tr>
<th>Country</th>
<th>Accept</th>
<th>Revision</th>
<th>Pending</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgium</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>China</td>
<td></td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>Colombia</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>1</td>
<td></td>
<td>5</td>
</tr>
<tr>
<td>Germany</td>
<td>2</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Iran</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japan</td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>KOREA, REPUBLIC OF</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>Mexico</td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Netherlands</td>
<td></td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Norway</td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Poland</td>
<td>1</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>South Africa</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Sweden</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>United States</td>
<td>1</td>
<td>6</td>
<td>3</td>
</tr>
</tbody>
</table>
Social Media Presence: Facebook

- Page Views: 94%
- Page Previews: 400%
- Page Likes: 200%
- Reach: 306%
- Post Engagement: 32%
- Page Follower: 200%
## Social Media Presence: LinkedIn

### Average audience reached

<table>
<thead>
<tr>
<th>Role</th>
<th>Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory Scientist</td>
<td>56</td>
</tr>
<tr>
<td>Pharmacist</td>
<td>48</td>
</tr>
<tr>
<td>Research/Graduate Assistant</td>
<td>37</td>
</tr>
<tr>
<td>University Professor/Lecturer</td>
<td>36</td>
</tr>
<tr>
<td>Student/Intern</td>
<td>26</td>
</tr>
<tr>
<td>Salesperson</td>
<td>24</td>
</tr>
<tr>
<td>CEO/Executive Director</td>
<td>21</td>
</tr>
<tr>
<td>Medical Assistant/Technician</td>
<td>20</td>
</tr>
<tr>
<td>Clinical Research Specialist</td>
<td>16</td>
</tr>
</tbody>
</table>

Data analysis based on most recent LinkedIn post
Alternative sampling strategies Committee

Jan-Willem Alffenaar, PhD, PharmD, Clinical Pharmacologist (Chair)
University Medical Center Groningen
University of Groningen, Groningen, The Netherlands

Christophe Stove, PhD (Vice-Chair)
Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
Committee Membership

- **Current Members**
  - Jan-Willem Alffenaar
  - Christophe Stove
  - Yngve Berqvist
  - Michael Boettcher
  - Begoña Delgado-Charro
  - Pleasant Hooper
  - Brian Keevil
  - Rafael Linden
  - Jan Gerard Maring
  - Roland Meesters

- **Past Members**
  - Leo Stolk
  - Birgit Koch
  - Constantinos Pistas
  - Remco Koster
  - Bert Ooms (retired)
  - Otto Halmingh (stopped because of policy change of the Company)
Activities

DBS Guideline

- This guideline defines key elements necessary for the validation of dried blood spot analysis.
- Guidance and criteria are given on the application of these validated methods in the routine analysis of
  - non-regulatory study samples from animal and human studies
  - samples from routine TDM.
Activities

- Guideline development
  - Drafted outline of the guideline
  - Draft of different chapters followed by monthly Skype meeting
  - Circulation of drafted chapter within committee for critical review and feedback
  - Final draft circulated within committee

- Presentation at IATDMCT Congress in Kyoto Japan.

- Artwork is being finalized (Sept 2018)

- Submission to TDM journal for publication (Oct-Nov 2018)
Activities

TIAFT 2018
26-30 / 08
GHENT BELGIUM
PROGRAM & ABSTRACT BOOK

IATDMCT & TIAFT Joint Young Scientist Symposium at TIAFT2018 (Ghent, Belgium)
Publications

Compass

- **March ‘18 edition:** Oral fluid – a suitable specimen for compliance testing in psychopharmacotherapy and substitution therapy by M Böttcher and O Beck
- **June ‘18 edition:** Dried blood spot sampling in direct oral anticoagulants, what is the future? by C Pistos
- **Sept ‘18 edition:** Measurement of testosterone concentration in dried blood samples with haematocrit correction by D Marshall and BG Keevil
Output

- Presentations
  - n ~ 10
- Peer reviewed papers related to alternative sampling:
  - n ~ 30
Clinical Toxicology and Drugs of Abuse Committee

**Aims**

- To provide evidence-based recommendations for CTDOA scientists, clinicians, laboratory and health care personal about of drugs of use and misuse
- To promote the knowledge and understanding of drug analysis, clinical toxicological normal and abnormal values and interpretation of results
- To enhance communication between scientists and physicians of all disciplines involved in CT of therapeutics and drugs of misuse
- To encourage the effective application of CT in all aspects of medicine, with the aim of optimizing clinical therapeutic use, avoid drug adverse reactions or interaction between drugs of use and misuse and maximizing the clinical and economic benefits
Clinical Toxicology and Drugs of Abuse Committee

Committee Achievements for 2018

- Organizing and participation in Symposia and workshops
  - Organization: Alcohol and Drugs (Rehovot, Israel, July, 2017), Alcohol and Gut -Liver Axis, Satellite Symposium for Research Society on Alcoholism (San Diego, CA, June 2018), Canadian Society for Pharmacological Sciences, Toronto, ON, Canada, July 2018;
  - Speakers: The Ontario Society for Clinical Chemistry (Toronto, ON, Canada — November 2017), Canadian Society for Clinical Chemistry (Ottawa, ON, Canada, June 2018), Symposium on Risk factors for Alcoholic Liver Disease in International Association for Biological Research on Alcoholism 2018 Congress, (Kyoto, Japan, September 2018)
Clinical Toxicology and Drugs of Abuse Committee

- **Participation in Symposia and workshops**
  - IATDMCT

- **Active participation in the Compass**

  Members of the Committee wrote articles for each issue published in the Compass.

New members of our Committee:

Cristiana Stefan  
Toronto  
Canada

Minodora Dobreanu  
Targu Mures  
Romania

Daniel Kolnick  
Haifa  
Israel
Participation in Symposia and workshops

- Proposals for Plenary Lectures, Symposia, workshops, and contributed papers for the 17th IATDMCT Congress, Iguaçu, Brazil, 22-25 September 2019.
- Symposium on Alcohol and Cancer, Rhode Island, USA, April 2019.
- Symposium on Alcohol and Microbiota, RSA, Minneapolis, USA, 2019.
- Symposium on Stellate cell and Liver Fibrosis, Toronto, Canada, 2019.

Active participation in the Compass

- We are going to participate with 6 reports during 2019.
Clinical Toxicology and Drugs of Abuse Committee

- **Active participation in supplying materials for the e-news, website, including educational materials**

  Kamisha Johnson Davis and Manuela Neuman will coordinate the contribution of the Communication Committee. Maria Shipkova (TDN Sc Committee) and Manuela Neuman will edit e-News for Communication Committee.

- **Participation in a review manuscript on**: Biomarkers for Drug-induced Liver Injury to be published in TDM Journal in 2019. Editor: Maria Shipkova.

- **Establishing Consortiums to facilitate**:
  - Multi-centric research projects
  - Inter-laboratory validation and quality control
  - Consensus documents and guidelines
  - Publications
Committee Initiatives for 2019

- Initiatives of the Working Groups
  - The Biomarkers Working Group
    - Innovative approach in personalized and precision medicine
    - Pharmacokinetic
    - Immuno-toxico-kinetics
    - Drug Discovery
    - Interaction between drugs of use and misuse
    - Herbal-induced injury to different organs
    - Infectious disease and therapeutic interactions
    - Biomarkers in hypersensitivity Syndrome
    - Pharmacogenetic and Justice
    - Continue collaboration between the members of the committee
    - Collaboration with several national and international scientific organization
Immunosuppressive Drugs Scientific Committee

Background & Purpose

- To provide evidence-based recommendations for TDM of immunosuppressive agents
- To promote the knowledge and understanding of immunosuppressive drug analysis and interpretation of results
- To enhance communication between scientists and physicians of all disciplines involved in TDM of immunosuppressive drugs
- To encourage the effective application of TDM in transplant medicine, with the aim of optimizing clinical drug use and maximizing the clinical and economic benefits

Chair: Mercè Brunet
Vice-Chair: Stein Bergan
Immunosuppressive Drugs Scientific Committee

Committee Achievements for 2018

- **Consensus Documents**
  - *Therapeutic Drug Monitoring of Tacrolimus-personalized Therapy: Second Consensus Report.* Status: editing the whole document to be published in TDM at the end of 2018. Participants: practically all members of the Immunosuppressive Drugs Scientific Committee (ISDs SC) and some members from the SC of PG. Coordinators: Mercè Brunet and Stein Bergan.

- **Participation in Symposia and workshops (I)**
  - IATDMCT Congress, Brisbane 2018. Active participation in symposiums (1, 2, 5, 14, 16) and contributed papers.
Immunosuppressive Drugs Scientific Committee

Committee Achievements for 2018

- Participation in Symposia and workshops (II)

- Active participation in the Compass
  - First report, *Insight miRNAs as Biomarkers in Clinical Transplantation* by O. Millán & M.Brunet, was published in COMPASS Vol17 issue 2, June 2018.
Immunosuppressive Drugs Scientific Committee

Committee Achievements for 2018

- Achievements of the Working Groups of the Immunosuppressive Drugs Committee
  - The Biomarkers Working Group*
    - Contribution of manuscript “Pharmacodynamic Monitoring of mTOR inhibitors” to Therapeutic Drug Monitoring Focus Issue. Participants: O. Millán, P. Marquet, E. Wieland, M. Brunet. Lead: M. Shipkova.
    *Leader: Uwe Christians
  - The Intracellular tacrolimus measurement Working Group*
    * Leader: Florian Lemaitre
Achievements of the Working Groups of the Immunosuppressive Drugs Committee (II)

- **Standardization of ISDs TDM Working Group**

  Immunosuppressive Drugs WG-ID was established by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).
  
  - Terms of Reference: The WG is devoted to the establishment of candidate reference procedures and reference materials for immunosuppressive drugs (ISDs) as cyclosporine, sirolimus, tacrolimus, everolimus, and mycophenolic acid (MPA). Demonstration of the current state of the art in ISDs-TDM by measurement comparison will define the need for harmonization or-if feasible standardization of measurement services.

  - Current projects:
    
    - Regulatory frame work: Submit to the JCTLM reference materials, measurement methods and measurement services established within the WG-ID.
    
    - Other projects, initiatives for 2019

  *Leaders: Christoph Seger, Loralie Langman*
Committee Initiatives for 2019

- **Participation in Symposia and workshops**
  - Proposals for Plenary Lectures, Symposia, workshops, and contributed papers for The 17th IATDMCT Congress in Iguaçu, Brazil, 22-25 September 2019.

- **Active participation in the Compass**
  - We are going to participate with 2 reports during 2019.

- **Active participation in supplying materials for the website, including educational materials**
  - Mercè Brunet and Stein Bergan will coordinate the contribution of the Committee.

- **Participation in a review manuscript on:** TDM and immunosuppressive drugs: originals and generics. With the participation of members of the ISDs Committee. To be published in TDM Journal in 2019. Leaders: T. Pawinski & P. Kunicki.
Committee Initiatives for 2019

- **Consider Establishing Consortiums to facilitate:**
  - Multicentric research projects
  - Inter-laboratory validation methodologies
  - Consensus documents and guidelines
Committee Initiatives for 2019

- **Initiatives of the Working Groups (I)**
  
  - **The Biomarkers Working Group**
    Second Consensus Document on Biomarkers of ISDs in Transplantation. Participants: all members of the BWG.
    Leader: Uwe Christians
  
  - **The Intracellular tacrolimus measurement Working Group**
    Consider an external quality control program
    Proposal: Coordinate a clinical trial to determine the therapeutic range for intracellular IS drugs concentrations. Participants: all members of the WG.
    Leader: Florian Lemaitre
  
  - **Standardization of ISD TDM Working Group (WG-ID)**
    The analytical standardisation driven by the IFCC and a committee co-chaired by L. Langman and C. Seger, and the implementation of the standardisation leading to all laboratories providing “identical” results, which will be driven by the ISDs Committee. Participants: M.J. Barten, S. Bergan, M. Brunet, U. Christians, B. De Winter, L. Elens, D.W. Holt, P.K: Kunicki, S. Masuda, D. Moes, T. Pawinski, L.M. Shaw, M. Shipkova, N. Tore Vethe, T. Van Gelder, P. Wallemacq, E. Wieland.
    Leaders: Christoph Seger, Loralie Langman
Initiatives of the Working Groups (II)

- Standardization of ISDs TDM Working Group (Cont.)

WG-ID Projects:

- Measurement comparison initiative aimed to assess the state of the art in ISD TDM
- Production of reference materials on method comparability.
- Establishment of reference methods to be listed in the JCTLM database
- Establishing reference procedures: Establishment of a reference laboratory network and a reference measurement service network

Leaders: Christoph Seger, Loralie Langman
## IATDMCT Immunosuppressive Drugs Committee Members

<table>
<thead>
<tr>
<th><strong>Chair</strong></th>
<th>Mercè</th>
<th>Barcelona, Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunet</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vice-Chair</strong></td>
<td>Stein</td>
<td>Oslo, Norway</td>
</tr>
<tr>
<td>Bergan</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surname</td>
<td>Forename</td>
<td>Location</td>
</tr>
<tr>
<td>Barten</td>
<td>Markus</td>
<td>Hamburg, Germany</td>
</tr>
<tr>
<td>Billaud</td>
<td>Eliane</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Budde</td>
<td>Klemens</td>
<td>Berlin, Germany</td>
</tr>
<tr>
<td>Christians</td>
<td>Uwe</td>
<td>Hannover, CO, USA</td>
</tr>
<tr>
<td>Cooper</td>
<td>Don</td>
<td>Manchester, UK</td>
</tr>
<tr>
<td>Elens</td>
<td>Laure</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>Hesselink (past Chair)</td>
<td>Dennis</td>
<td>Rotterdam, Netherlands</td>
</tr>
<tr>
<td>Holt</td>
<td>David W.</td>
<td>London, UK</td>
</tr>
<tr>
<td>Johnson-Davis</td>
<td>Kamisha</td>
<td>Salt Lake City, USA</td>
</tr>
<tr>
<td>Kunicki</td>
<td>Pawel K.</td>
<td>Warsaw, Poland</td>
</tr>
<tr>
<td>Langman</td>
<td>Loralie J.</td>
<td>Rochester, MN, USA</td>
</tr>
<tr>
<td>Members</td>
<td>Surname</td>
<td>Forename</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------</td>
<td>----------</td>
</tr>
<tr>
<td>Lemaitre</td>
<td>Florian</td>
<td></td>
</tr>
<tr>
<td>MacPhee</td>
<td>Iain</td>
<td></td>
</tr>
<tr>
<td>Marquet</td>
<td>Pierre</td>
<td></td>
</tr>
<tr>
<td>Mason</td>
<td>Donald</td>
<td></td>
</tr>
<tr>
<td>Masuda</td>
<td>Satohiro</td>
<td></td>
</tr>
<tr>
<td>Mathew</td>
<td>Binu</td>
<td></td>
</tr>
<tr>
<td>Millán</td>
<td>Olga</td>
<td></td>
</tr>
<tr>
<td>Milone</td>
<td>Michael</td>
<td></td>
</tr>
<tr>
<td>Moes</td>
<td>Dirk-Jan</td>
<td></td>
</tr>
<tr>
<td>Morris</td>
<td>Ray</td>
<td></td>
</tr>
<tr>
<td>Noceti</td>
<td>Ofelia</td>
<td></td>
</tr>
<tr>
<td>Oellerich</td>
<td>Michael</td>
<td></td>
</tr>
<tr>
<td>Pawinski</td>
<td>Tomasz</td>
<td></td>
</tr>
<tr>
<td>Seger</td>
<td>Christoph</td>
<td></td>
</tr>
<tr>
<td>Shaw</td>
<td>Les</td>
<td></td>
</tr>
<tr>
<td>Shipkova</td>
<td>Maria</td>
<td></td>
</tr>
<tr>
<td>Taylor</td>
<td>Paul</td>
<td></td>
</tr>
<tr>
<td>Members</td>
<td>Surname</td>
<td>Forename</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Members</td>
<td>van Gelder</td>
<td>Teun</td>
</tr>
<tr>
<td></td>
<td>van Schaik</td>
<td>Ron</td>
</tr>
<tr>
<td></td>
<td>Vethe</td>
<td>Nils Tore</td>
</tr>
<tr>
<td></td>
<td>Vinks</td>
<td>Sander</td>
</tr>
<tr>
<td></td>
<td>Wallemacq</td>
<td>Pierre</td>
</tr>
<tr>
<td></td>
<td>Wang</td>
<td>Ping</td>
</tr>
<tr>
<td></td>
<td>Wieland</td>
<td>Eberhard</td>
</tr>
</tbody>
</table>
# Members of the PGx Committee

<table>
<thead>
<tr>
<th>Chair</th>
<th>Vice Chair</th>
<th>Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Haufroid</td>
<td>Nicolas Picard</td>
<td>Iain McPhee-St George's University London, UK</td>
</tr>
<tr>
<td>University of Louvain, BE</td>
<td>Limoges University Hospital, FR</td>
<td>Erasmus MC Rotterdam, NL</td>
</tr>
<tr>
<td>Teun van Gelder</td>
<td>Ron van Schaik</td>
<td>Ron van Schaik-Erasmus MC Rotterdam, NL</td>
</tr>
<tr>
<td>Erasmus MC Rotterdam, NL</td>
<td>Laure Elens</td>
<td>Laure Elens-University of Louvain, Brussels, BE</td>
</tr>
<tr>
<td>Mark Linder</td>
<td>Stein Bergan</td>
<td>Stein Bergan-Oslo University Hospital, NO</td>
</tr>
<tr>
<td>University of Louisville, USA</td>
<td>Werner Steimer</td>
<td>Werner Steimer-Technische Universitaet Munchen, GER</td>
</tr>
<tr>
<td>Jana Stojanova</td>
<td>Andrew Somogyi</td>
<td>Jesse Swen-Leiden University MC, NL</td>
</tr>
<tr>
<td>University of Valparaiso, Chile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven Wong</td>
<td>Andrew Somogyi</td>
<td>Jana Stojanova-University of Valparaiso, Chile</td>
</tr>
<tr>
<td>Wake Forest School of Med., USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tsuyoshi Fukuda</td>
<td></td>
<td>Andrew Somogyi-University of Adelaide, Australia</td>
</tr>
<tr>
<td>Cincinnati children's Hospital, USA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Recent activities

• Publications in TDM journal


• Contribution in IATDMCT compass

Picard N and Haufroid V on behalf of the Pharmacogenetics Committee. Pharmacogenetic-based personalized therapy: The French national network of pharmacogenetics (RNPGX) proposed levels of evidence and recommendations. IATDMCT Compass March 2017: 4-5

Next contribution to the IATDMCT compass; November 2018
Recent activities

• Organization of the PGx session for Brisbane 2018

Linder M and Somogyi A (chairs of the PGx session) Pre-emptive pharmacogenetics testing: is this the right approach?

1. Linder M, USA
2. Guchelaar H.J., The Netherlands
3. Dunnenberger M, USA
4. Wang Y.T., China

• Validation of minimal NGS panel for PGx applications

Picard N and Haufroid V, on behalf of the Pharmacogenetics Committee, in the French national network of pharmacogenetics (RNPGX). Panel in validation
Connections

- AACC Personalized Medicine Division (RvS)
- IFCC Pharmacogenetic Task Force (RvS)
- ESPT (European Soc Pharmacogenetics) (RvS)
- EMA Pharmacogenetics Working Group (RvS)
- Dutch Pharmacy Group Pharmacogenetics (RvS, JS)
- Dutch Clinical Chem Pharmcogenetics Network (RvS, JS)
- French National Network of Pharmacogenetics, RNPGx (NP, VH)
- European Pharmacogenetics Research Network - EuPIC (RvS, VH, NP, LE, JS)
- H2020 European Project (UPGX) (JS, RvS)
- CPIC (RvS, VH, ML, JSv, JSt)
Future activities

• Make proposal for IATDMCT PGx session in Foz Do Iguassu, Brazil, 2019
• Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass)
• Explore the need for updated PGx guidelines in immunosuppressive therapy
TDM in Oncology

William Clarke, Chair
Johns Hopkins Hospital, USA

Edward Chu
University of Pittsburgh Cancer Center, USA

Jennifer Martin, Vice-Chair
University of Newcastle, NSW Australia

Alan Foothi
Karolinska Institute, Sweden

Yusuke Tanigawara
Keio University SOM, Japan

Paula Schaiquevich
Unidad de Farmacocinetica Clinica, Argentina

Jan Beumer
University of Pittsburgh, USA

Sal Salamone
Saladax Biomedical, USA

Erik van Maarseveen
UMC Utrecht, Netherlands

Yuichi Ando
Nagoya University Hospital, Japan

Etienne Chatelut
IUCT-Oncopele, France

Markus Joerger
Cantonal Hospital, Switzerland
Title of slide

- TDM in Oncology Guidelines
  - 5-Fluorouracil (completed)
  - Imatinib (draft in progress)
  - Paclitaxel (just starting)

- Publications
  - Review article to TDM journal (in revision)
  - Articles in Compass
  - 5-FU Guidline

- Other activities
  - Development of SOP for guideline review and publication
  - Transition of committee leadership
Toxicology and Environmental Health Scientific Committee

Nicolas Venisse  
Toxicologie et Pharmacocinétique

David Kinniburgh  
Alberta Centre for Toxicology
Symposium at IATDMCT conferences

- Kyoto conference: A new Scientific Committee on Toxicology and Environmental Health at IATDMCT.

- Brisbane conference: Alternative matrix for the determination of human exposure to environmental pollutants
Articles for Compass

- Presentation of the new SC committee (N Venisse, 2017 issue)

- Report from the Society of Toxicology (SOT) conference in San Antonio (S Haddad, June 2018 issue)

- General paper on Bioanalytical validation in Environmental Health Toxicology (Antoine Dupuis, Sept 2018)

- Report on Biomonitoring program in Alberta, Canada (D Kinniburgh, 2018)
Future contributions

- Development of a Bioanalytical validation guideline in environmental health toxicology. The objective is to develop an innovative tool allowing standardization and avoiding poor quality bioanalytical results. A questionnaire will be send to members of the scientific committee in order to develop this guideline. The consensus document could be presented at the 2019 conference as a post-congress workshop and published in a peer-reviewed journal.

- Symposium for 2019 conference
- Articles submission for Compass
- Proposal for a joint symposium at Society of Toxicology conference: Sami Haddad is an active member of both societies.
Young Scientists Committee (YSC)

Indy Sandaradura  
Australia

Takehito Yamamoto  
Japan

Laure Elens  
Belgium

Kamisha Johnson-Davies  
USA

Markus R. Meyer (Chair)  
Germany

Brenda de Winter (Vice-Chair)  
The Netherlands

Sarah Wille  
Belgium

Nicolas Picard  
France

Sumith K Mathew  
India

Tomoyuki Mizuno  
USA
Joint Symposium with TIAFT

- YSC of IATDMCT and YSC of TIAFT organized a successful joint symposium at the TIAFT conference in Ghent 2018
- Sunday 26th of August 09:00 – 12:30 h
- Brenda de Winter gave a talk about CT

→ over 150 YS attended
Activities in Brisbane

- Wednesday 19 September 2018 - IATDMCT Young Scientist Symposium at 10:30-12:30 h
- Monday 17 September 2018 - YS Night Out “Young Scientists Dinner“ at 19:00 h
- YS get together right before the opening ceremony
- Young Scientist Awards (oral/poster)
- 23 entries (oral), 39 entries (poster)
Frequent Compass Contributions (YS Corner)

- March 2018: Introducing new members of the YSC
- September: Brisbane congress activities
Upcoming topics

- Succession?
  - Markus will step down as chair in 2019
  - Takehito will step down in 2018 (Yusuke)
- Joint symposia with related YSC (TIAFT?)
- Increase YS activities at annual congresses
  - Expert speed dating